KAYLAN FELKER: Open Payments
NPI 1639720618 · GULFPORT, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$811 in 33 payments from 15 companies in 2025. Trend: 2023 $255 · 2024 $433 · 2025 $811
Food & beverage: $811
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 7 | $195 |
| Vifor Pharma, Inc. | 3 | $85 |
| Fresenius USA Marketing, Inc. | 4 | $84 |
| Amgen Inc. | 4 | $81 |
| Novo Nordisk Inc | 3 | $77 |
| NxStage Medical, Inc. | 1 | $66 |
| Apellis Pharmaceuticals, Inc. | 2 | $40 |
| AstraZeneca Pharmaceuticals LP | 2 | $35 |
| ANI Pharmaceuticals, Inc. | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
Products named: Vanrafia, Veltassa, VELPHORO, TAVNEOS, Ozempic, NXSTAGE SYSTEM ONE, FARXIGA, PURIFIED CORTROPHIN GEL.
Industry payments across MS — which companies pay providers there.
